Descartes Systems Group (DSGX) reported record Q2 revenue of $201 million, up 12% year-over-year, driven by strong demand for its trade intelligence and logistics solutions. The company's strategic acquisitions are bolstering its growth, though integration risks remain. Analysts suggest a potential 30% stock increase.
Topic Studios navigates the challenging film landscape with major successes like 'Club Kid' and 'The Debut'. Their fantasy drama 'Wicker' saw unexpected viral fame thanks to TikTok and IKEA, highlighting the power of organic online buzz in today's market.
New Phase 2 data from the DeLLphi-309 study suggest tarlatamab can be effectively administered at extended intervals (every three or four weeks) in relapsed SCLC patients, maintaining comparable efficacy and safety to the standard every-two-week regimen. This offers greater treatment flexibility.
North Dakota State Bison, strong at the FBS level, clash with Air Force Falcons in their Mountain West conference opener. Both teams dominated their season openers with shutouts. Key betting odds favor NDSU slightly.
Apple's digital driver's license in Wallet offers enhanced security and convenience, but its adoption is still limited to select US states. Learn how to add yours and understand its current capabilities and future potential.
A new smart pen, developed by Italian researchers, can identify writing difficulties like dysgraphia in children much earlier by analyzing pressure and movement. The study involved over 700 primary and lower secondary students.
A Standard Chartered analyst has set a price target for Sky Protocol's SKY token, predicting a 400% increase by 2028. The analyst draws parallels between Sky Protocol and a federal bank, highlighting its stablecoin issuance and governance structure.
Cody Lightning’s new film ‘Smudge the Blades’ offers a refreshing take on the underdog sports genre, focusing on the resilience of an Indigenous youth hockey team facing systemic racism and personal struggles, rather than typical motivational speeches.
A Phase 1b trial of subcutaneous tarlatamab for extensive-stage small cell lung cancer (ES-SCLC) demonstrated a favorable safety profile with low rates of severe adverse events, including cytokine release syndrome (CRS). The new administration route showed comparable drug exposure to the intravenous form and preliminary antitumor activity, supporting further development.